QHSLab (USAQ) 10-Q 10 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Nov. 11, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	000-19041
Entity Registrant Name	QHSLab, Inc
Entity Central Index Key	0000856984
Entity Tax Identification Number	30-1104301
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	901 Northpoint Parkway
Entity Address, Address Line Two	Suite 302
Entity Address, Address Line Three	West Palm
Entity Address, City or Town	Beach
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33407
City Area Code	(929)
Local Phone Number	379-6503
Title of 12(b) Security	Common Stock, $0.0001 Par Value
Trading Symbol	USAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		9,315,508

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current Assets:
Cash and cash equivalents	$ 237,934	$ 286,855
Accounts receivable, net	58,094	70,474
Inventory	97,959	65,740
Prepaid expenses and other current assets	49,335	22,713
Total current assets	443,322	445,782
Non-current assets:
Capitalized software development costs, net	186,159	186,271
Intangible assets, net	1,522,360	1,576,444
Total assets	2,151,841	2,208,497
Current Liabilities:
Accounts payable	149,995	20,370
Other current liabilities	85,612	58,615
Loans payable, current portion	297,225	253,865
Convertible notes payable, current portion	1,123,811	542,104
Total current liabilities	1,656,643	874,954
Non-current liabilities:
Accrued interest expenses		6,521
Loans payable, non-current portion	208,999	402,956
Convertible notes payable, non-current portion		100,000
Total non-current liabilities	208,999	509,477
Total liabilities	1,865,642	1,384,431
Commitments and contingencies (Note 13)
Stockholders’ Equity:
Common stock, 900,000,000 shares authorized, $0.0001 par value; 9,315,508 and 8,756,093 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	932	876
Unearned stock compensation		(6,968)
Additional paid-in capital	3,583,594	3,348,681
Accumulated deficit	(3,298,699)	(2,518,895)
Total stockholders’ equity	286,199	824,066
Total liabilities and stockholders’ equity	2,151,841	2,208,497
Series A Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock	108	108
Series A-2 Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock	$ 264	$ 264

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Common stock, shares authorized	900,000,000	900,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares issued	9,315,508	8,756,093
Common stock, shares outstanding	9,315,508	8,756,093
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	1,080,092	1,080,092
Preferred stock, shares outstanding	1,080,092	1,080,092
Series A-2 Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	2,644,424	2,644,424
Preferred stock, shares outstanding	2,644,424	2,644,424
Preferred Stock [Member]
Preferred stock, shares authorized	10,000,000	10,000,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Revenue	$ 269,323	$ 324,479	$ 975,469	$ 1,084,436
Cost of revenue	143,716	167,393	490,965	586,651
Gross profit	125,607	157,086	484,504	497,785
Operating Expenses:
Sales and marketing	154,620	181,820	387,687	455,128
General and administrative	107,965	149,741	321,573	354,831
Research and development	48,405	19,609	135,998	62,901
Amortization	18,028	18,028	54,084	18,028
Total Operating Expenses	329,018	369,198	899,342	890,888
Net operating loss	(203,411)	(212,112)	(414,838)	(393,103)
Interest expense	106,704	88,658	362,946	106,680
Loss on extinguishment of debt			2,020
Net loss	$ (310,115)	$ (300,770)	$ (779,804)	$ (499,783)
Basic and diluted net loss per share	$ (0.03)	$ (0.03)	$ (0.09)	$ (0.07)
Weighted average shares outstanding: (Basic and diluted)	9,068,225	8,646,399	8,889,836	7,570,228

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series A-2 Preferred Stock [Member]	Common Stock [Member]	Unearned Stock Compensation [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 108		$ 656	$ (124,479)	$ 1,264,108	$ (1,748,719)	$ (608,326)
Beginning balance, shares at Dec. 31, 2020	1,080,092		6,562,735
Shares issued for services			$ 15	(89,419)	89,985		581
Shares issued for services, shares			150,000
Conversion of notes payable			$ 50		194,161		194,211
Conversion of notes payable, shares			496,718
Stock-based compensation expense					8,920		8,920
Net loss						(86,686)	(86,686)
Cancellation of shares			$ (10)		10
Cancellation of shares, shares			(100,000)
Amortization of unearned compensation				67,812			67,812
Ending balance, value at Mar. 31, 2021	$ 108		$ 711	(146,086)	1,557,184	(1,835,405)	(423,488)
Ending balance, shares at Mar. 31, 2021	1,080,092		7,109,453
Beginning balance, value at Dec. 31, 2020	$ 108		$ 656	(124,479)	1,264,108	(1,748,719)	(608,326)
Beginning balance, shares at Dec. 31, 2020	1,080,092		6,562,735
Net loss							(499,783)
Ending balance, value at Sep. 30, 2021	$ 108		$ 868	(10,451)	2,842,523	(2,248,502)	584,546
Ending balance, shares at Sep. 30, 2021	1,080,092		8,679,170
Beginning balance, value at Mar. 31, 2021	$ 108		$ 711	(146,086)	1,557,184	(1,835,405)	(423,488)
Beginning balance, shares at Mar. 31, 2021	1,080,092		7,109,453
Conversion of notes payable			$ 26		132,049		132,075
Conversion of notes payable, shares			263,572
Stock-based compensation expense					8,921		8,921
Net loss						(112,327)	(112,327)
Share purchase			$ 5		29,995		30,000
Share purchase, shares			50,000
Amortization of unearned compensation				36,594			36,594
Shares issued for services, net of cancellation			$ (7)	62,750	(41,893)		20,850
Shares issued for services, net of cancellation, shares			(70,000)
Shares issued for asset purchase			$ 125		862,375		862,500
Shares issued for asset purchase, shares			1,250,000
Ending balance, value at Jun. 30, 2021	$ 108		$ 860	(46,742)	2,548,631	(1,947,732)	555,125
Ending balance, shares at Jun. 30, 2021	1,080,092		8,603,025
Shares issued for services			$ 4	16,218	33,196		49,418
Shares issued for services, shares			40,000
Warrants issued with convertible note payable					221,779		221,779
Stock-based compensation expense					8,921		8,921
Net loss						(300,770)	(300,770)
Amortization of unearned compensation				20,073			20,073
Shares issued in a funding			$ 4		29,996		30,000
Shares issued in a funding, shares			36,145
Ending balance, value at Sep. 30, 2021	$ 108		$ 868	(10,451)	2,842,523	(2,248,502)	584,546
Ending balance, shares at Sep. 30, 2021	1,080,092		8,679,170
Beginning balance, value at Dec. 31, 2021	$ 108	$ 264	$ 876	(6,968)	3,348,681	(2,518,895)	824,066
Beginning balance, shares at Dec. 31, 2021	1,080,092	2,644,424	8,756,093
Shares issued for services				3,484			3,484
Shares issued for services, shares
Conversion of notes payable			$ 6		27,919		27,925
Conversion of notes payable, shares			59,415
Warrants issued with convertible note payable					2,020		2,020
Stock-based compensation expense					8,920		8,920
Net loss						(190,304)	(190,304)
Ending balance, value at Mar. 31, 2022	$ 108	$ 264	$ 882	(3,484)	3,387,540	(2,709,199)	676,111
Ending balance, shares at Mar. 31, 2022	1,080,092	2,644,424	8,815,508
Beginning balance, value at Dec. 31, 2021	$ 108	$ 264	$ 876	(6,968)	3,348,681	(2,518,895)	824,066
Beginning balance, shares at Dec. 31, 2021	1,080,092	2,644,424	8,756,093
Net loss							(779,804)
Ending balance, value at Sep. 30, 2022	$ 108	$ 264	$ 932		3,583,594	(3,298,699)	286,199
Ending balance, shares at Sep. 30, 2022	1,080,092	2,644,424	9,315,508
Beginning balance, value at Mar. 31, 2022	$ 108	$ 264	$ 882	(3,484)	3,387,540	(2,709,199)	676,111
Beginning balance, shares at Mar. 31, 2022	1,080,092	2,644,424	8,815,508
Shares issued for services				3,484			3,484
Stock-based compensation expense					8,921		8,921
Net loss						(279,385)	(279,385)
Ending balance, value at Jun. 30, 2022	$ 108	$ 264	$ 882		3,396,461	(2,988,584)	409,131
Ending balance, shares at Jun. 30, 2022	1,080,092	2,644,424	8,815,508
Conversion of notes payable			$ 25		49,975		50,000
Conversion of notes payable, shares			250,000
Warrants issued with convertible note payable					81,183		81,183
Stock-based compensation expense					6,000		6,000
Net loss						(310,115)	(310,115)
Share purchase			$ 25		49,975		50,000
Share purchase, shares			250,000
Ending balance, value at Sep. 30, 2022	$ 108	$ 264	$ 932		$ 3,583,594	$ (3,298,699)	$ 286,199
Ending balance, shares at Sep. 30, 2022	1,080,092	2,644,424	9,315,508

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating activities
Net loss	$ (779,804)	$ (499,783)
Adjustments to reconcile net loss to net cash from operating activities:
Allowance for doubtful accounts	9,173
Amortization	91,315	18,028
Amortization of debt and warrant issuance costs	267,889	54,881
Stock-based compensation	23,842	26,762
Shares issued for services	6,968	195,328
Loss on extinguishment of debt	2,020
Changes in operating assets and liabilities:
Accounts receivable	3,207	22,184
Inventory	(32,219)	(1,535)
Prepaid expenses and other current assets	(26,622)	(25,723)
Accounts payable	129,625	(56,808)
Other current liabilities	(15,717)
Accrued interest	39,118	30,535
Cash flows from operating activities	(281,205)	(236,131)
Investing activities:
Capitalized software	(37,119)	(108,165)
Cash flows from investing activities	(37,119)	(108,165)
Financing activities:
Proceeds from sales of common stock	50,000	30,000
Issuance of convertible notes payable	400,000	850,000
Proceeds of loan borrowings	128,500	86,000
Repayments of loan borrowings	(279,097)	(87,735)
Payment of debt issuance costs	(30,000)	(85,000)
Cash flows from financing activities	269,403	793,265
Change in cash	(48,921)	448,969
Cash and cash equivalents – beginning of year	286,855	94,342
Cash and cash equivalents - end of period	237,934	543,311
Supplemental disclosures of cash flow activity:
Cash paid for interest	55,939	21,265
Cash paid for taxes
Supplemental noncash investing and financing activity:
Debt and accrued interest converted to shares of common stock	77,925	326,286
Debt and common stock issued for intangible assets (Note 5)		1,612,500
Common stock issued for debt issuance costs		30,000
Warrants issued in conjunction with convertible note payable	$ 81,183	$ 221,779

The Company

The Company	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	Note 1. The Company QHSLab, Inc. (f/k/a USA Equities Corp.) (the “Company”, or the “Registrant”) was incorporated in Delaware on September 1, 1983 . On April 19, 2022, the Company changed its name to QHSLab, Inc. The Company is a medical device technology and software-as-a-service (“SaaS”) company focused on enabling primary care physicians (“PCP’s”) to increase their revenues by providing them with relevant, value-based tools to evaluate and treat chronic disease as well as provide preventive care through reimbursable procedures.

Going Concern

Going Concern	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 2. Going Concern The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since inception, has negative operational cash flows and only began recognizing revenues in the fourth quarter of fiscal 2020. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The continuation of the Company’s business is dependent upon its ability to achieve profitability and positive cash flows and, pending such achievement, future issuances of equity or other financings to fund ongoing operations. However, access to such funding may not be available on commercially reasonable terms, if at all. These condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Note 3. Basis of Presentation The condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of only normal recurring accruals, necessary for a fair statement of financial position, results of operations, and cash flows. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes included in our Annual Report on Form 10- K for the year ended December 31, 2021. The accounting policies are described in the “Notes to the Consolidated Financial Statements” in the 2021 Annual Report on Form 10-K and updated, as necessary, in this Form 10-Q. The year-end balance sheet data presented for comparative purposes was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. Reclassifications Certain reclassifications were made to the prior condensed consolidated financial statements to conform to the current period presentation. There was no change to the previously reported net loss. Risks Related to COVID-19 Pandemic The COVID-19 pandemic is affecting the United States and global economies and may affect the Company’s operations and those of third parties on which the Company relies. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic are difficult to assess or predict, the impact of the COVID-19 pandemic could negatively impact the Company’s short-term and long-term liquidity. The ultimate impact of the COVID-19 pandemic is highly uncertain and the Company does not yet know the full extent of potential impacts on its business, finances or the global economy as a whole. However, these effects could have a material impact on the Company’s liquidity, capital resources and operations. Accounting Policies Use of Estimates Principles of Consolidation Cash and Cash Equivalents Accounts Receivable Inventories Capitalized Software Development Costs Internal-Use Software The estimated useful lives of software are reviewed at least annually and will be tested for impairment whenever events or changes in circumstances occur that could impact the recoverability of the assets. Capitalized software development costs for internal-use software net of amortization expense totaled $ 186,159 186,271 37,231 0 no Intangible Assets Business Combination, Related Issues, Initial Measurement Intangibles, General Intangibles Other Than Goodwill Schedule of Indefinite-Lived Intangible Assets U.S. Method Patent 13.4 Web Domain Indefinite life Trademark Indefinite life The estimated useful lives and carrying value of the assets are reviewed at least annually or whenever events or circumstances may result in an impact to the value of the assets. Convertible Notes Payable Derivatives and Hedging Debt with Conversion and Other Options Revenue Recognition Pursuant to ASC Topic 606, Revenue from Contracts with Customers, To determine the revenue to be recognized for transactions that the Company determines are within the scope of ASC 606, the Company follows the established five-step framework as follows: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract(s); (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract(s); and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company sells allergy diagnostic-related products and immunotherapy treatments to physicians. Revenue is recognized once the Company satisfies its performance obligation which occurs at the point in time when title and possession of products have transitioned to the customer, typically upon delivery of the products. During 2022, the Company began entering into SaaS subscription agreements to provide physicians with access to the Company’s proprietary internally-developed QHSLab platform software that provides clinical decision support and patient monitoring The Company includes shipping and handling fees billed to customers in revenue. There are several practical expedients and exemptions allowed under ASC 606 that impact timing of revenue recognition and disclosures. The Company elected to treat similar contracts as a portfolio of contracts, as allowed under ASC 606. The contracts that fall within the portfolio have the same terms and management has the expectation that the result will not be materially different from the consideration of each individual contract. Research and Development For the three months ended September 30, 2022 and 2021, there were $48,405 and $19,609 of research and development expenses incurred, respectively. For the nine months ended September 30, 2022 and 2021, there were $ 135,998 62,901 of research and development expenses incurred, respectively. Stock-based Compensation Share Based Payment Earnings Per Common Share Income Taxes Accounting for Income Taxes, The Company has net operating losses of $ 3,298,699 begin to expire in 2027 Recently Issued Accounting Standards In August 2020, the Financial Accounts Standards Board (“FASB”) issued Accounting Standards Updates (“ASU”) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) This Quarterly Report on Form 10-Q does not discuss recent pronouncements that are not anticipated to have a current and/or future impact on or are unrelated to the Company’s financial condition, results of operations, cash flows or disclosures.

Accounts Receivable

Accounts Receivable	9 Months Ended
	Sep. 30, 2022
Credit Loss [Abstract]
Accounts Receivable	Note 4. Accounts Receivable Accounts receivable is recorded in the condensed consolidated balance sheets when customers are invoiced for revenue to be collected and there is an unconditional right to receive payment. Timing of revenue recognition may differ from the timing of invoicing customers resulting in deferred revenue until the Company satisfies its performance obligation. Accounts receivable is presented net of an allowance for potentially uncollectible accounts. During the period ended September 30, 2022, the Company established an allowance for potentially uncollectible accounts that represents future expected credit losses over the life of the receivables based on past experience, current information and forward-looking economic considerations. The beginning and ending balances of accounts receivable, net of allowance, are as follows: Schedule of Accounts Receivable September 30, December 31, Accounts receivable $ 67,267 $ 70,474 Allowance for doubtful accounts (9,173 ) - Accounts receivable, net $ 58,094 $ 70,474

Capitalized Software and Intang

Capitalized Software and Intangible Assets	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Capitalized Software and Intangible Assets	Note 5. Capitalized Software and Intangible Assets Non-current assets consist of the following at September 30, 2022 and December 31, 2021: Schedule of Intangible Assets Estimated September 30, December 31, Capitalized Software 3.0 $ 223,390 $ 186,271 Accumulated amortization (37,231 ) - Capitalized Software, net $ 186,159 $ 186,271 Intangible Assets: U.S. Method Patent 13.4 $ 967,500 $ 967,500 Web Domain N/A 161,250 161,250 Trademark N/A 483,750 483,750 Total Intangible Assets $ 1,612,500 $ 1,612,500 Accumulated amortization (90,140 ) (36,056 ) Intangible assets, net $ 1,522,360 $ 1,576,444 Capitalized software represents the development costs for the Company’s internal-use QHSLab platform software. The Company completed testing of its QHSLab platform software application at the end of the first quarter of 2022 and began to amortize the capitalized expenses on a straight-line basis over the useful life of the software. As of September 30, 2022 and December 31, 2021 there was $ 37,231 0 no The intangible assets represent the value the Company paid to acquire the trademark “AllergiEnd”, the web domain “AllergiEnd.com” along with the U.S. Method Patent registration relating to the allergy testing kit and related materials the Company distributes to physician clients. The Company acquired the intangible assets from MedScience Research Group as of June 23, 2021 for total consideration of $ 1,612,500 Business Combination, Related Issues, Initial Measurement. Intangibles, General Intangibles Other Than Goodwill 54,084 18,028 of

Loans Payable

Loans Payable	9 Months Ended
	Sep. 30, 2022
Loans Payable
Loans Payable	Note 6. Loans Payable On June 23, 2021, the Company entered into a purchase agreement to acquire certain assets from MedScience Research Group, Inc (“MedScience”) (See Note 5 for additional information). As part of that purchase agreement, the Company issued a Promissory Note with a principal sum of $ 750,000 467,807 644,158 On March 2, 2022, the Company entered into a fixed-fee short-term loan with its merchant bank and received $ 128,500 The loan payable is due in August 2023 and is recorded in current liabilities on the Company’s condensed consolidated balance sheets. The loan is repaid by the merchant bank withholding an agreed-upon percentage of payments they process on behalf of the Company with a minimum of $ 16,305 41,768 fixed-fee short-term loan with the same merchant bank had a balance of $ 16,793

Convertible Notes Payable

Convertible Notes Payable	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Convertible Notes Payable	Note 7. Convertible Notes Payable Convertible notes payable at September 30, 2022 and December 31, 2021, consist of the following: Schedule of Convertible Notes Payable September 30, December 31, Note 1 – Accredited investors $ - $ 25,000 Note 2 – Shareholder 100,000 100,000 Note 3 – Mercer Note 706,000 756,000 Note 4 – Mercer Note #2 440,000 - Total 1,246,000 881,000 Debt discount and issuance costs (122,189 ) (238,896 ) Total convertible notes payable 1,123,811 642,104 Less: current portion 1,123,811 542,104 Non-current portion $ - $ 100,000 Note 1 – Effective December 23, 2020, the Company issued a Convertible Promissory Note in the principal amount of $ 25,000 September 25, 2020 0 2,555 On February 23, 2022 the shareholder the outstanding principal of $ 25,000 59,415 0.47 14,854 0.705 Note 2 – Effective May 7, 2021, the Company issued a Convertible Promissory Note in the principal amount of $ 100,000 10 September 30, 2022 The Company may satisfy the Note upon maturity or Default, as defined, by the issuance of common shares at a conversion price equal to the greater of a 25% discount to the 15-day average market price of the Company’s common stock or $0.50. The principal and interest accrued are convertible at any time through the maturity date of September 30, 2022 at the option of the holder using the same conversion calculation 14,000 6,521 Note 3 – Effective August 10, 2021, the Company entered into a Securities Purchase Agreement with an accredited investor pursuant to which it issued to the investor an Original Issue Discount Secured Convertible Promissory Note (the “$806,000 Note”) in the principal amount of $ 806,000 930,000 750,000 The principal amount of the $806,000 Note and all interest accrued thereon is payable on August 10, 2022, and is secured by a lien on substantially all of the Company’s assets. The $806,000 Note provides for interest at the rate of 5 0.65 0.65 0.65 On November 11, 2021, Mercer Street Global Opportunity Fund, LLC (“Mercer Fund”), converted $ 50,000 76,923 0.65 The 930,000 three years 1.25 $806,000 As a result of the issuance of a $ 440,000 0.20 0.20 Mercer Fund converted $ 50,000 250,000 0.20 On October 17, 2022, the Company received notice from the manager of Mercer Fund of its agreement to forebear from the exercise of any rights it might have as a result of any defaults under the $806,000 Note and the related documents between the Company and the Mercer Fund, provided that the Mercer Fund The $806,000 Note continues to accrue interest at 5 As of September 30, 2022, all original issue discount and debt issuance costs, including the allocated relative fair value of the Warrants, have been recognized. The remaining principal balance of $ 706,000 $806,000 43,273 0 $806,000 15,446 204,835 34,060 Note 4 – Effective July 19, 2022, the Company entered into a Securities Purchase Agreement with Mercer Fund pursuant to which it issued an Original Issue Discount Secured Convertible Promissory Note (the “$440,000 Note”) in the principal amount of $ 440,000 550,000 400,000 The principal amount of the $440,000 Note and all interest accrued thereon is payable on July 19, 2023, and are secured by a lien on substantially all of the Company’s assets. The $440,000 Note provides for interest at the rate of 5 0.20 The $440,000 Note provides for various events of default similar to those provided for in similar transactions, including the failure to timely pay amounts due thereunder. The Note provides further that the Company will be liable to the Buyer for various amounts, including the cost of a buy-in, if the Company shall default in its obligation to register the shares issuable upon conversion of the Note for sale by the Buyer under the Securities Act or otherwise fails to facilitate Buyer’s sale of the shares issuable upon conversion of the Note as required by the terms of the Note. The 550,000 0.50 The Registration Rights Agreement requires the Company to file with the Securities and Exchange Commission within 60 days following the closing of the issuance of the $440,000 Note, a registration statement (the “Registration Statement”) with respect to all shares which may be acquired upon conversion of the $440,000 Note and exercise of the Warrant (the “Registrable Securities”) and to cause the Registration Statement to be declared effective no later than 90 days after the date of the issuance of the $440,000 Note, provided, that if the Company is notified by the SEC that the Registration Statement will not be reviewed or is no longer subject to further review and comments, the Company shall cause the Registration Statement to be declared effective on the fifth trading day following the date on which the Company is so notified. The Company is to cause the Registration Statement to remain continuously effective until all Registrable Securities covered by such Registration Statement have been sold, or may be sold pursuant to Rule 144 without the volume or other limitations of such rule, or are otherwise not required to be registered in reliance upon the exemption in Section 4(a)(1) or 4(a)(7) under the Securities Act. The Company accounts for the allocation of its issuance costs to its Warrants in accordance with ASC 470-20, Debt with Conversion and Other Options The Company estimated the fair value of the Warrants utilizing the Black-Scholes pricing model, which is dependent upon several assumptions such as the expected term of the Warrants, expected volatility of the Company’s stock price over the expected term, expected risk-free interest rate over the expected term and expected dividend yield rate over the expected term. The Company believes this valuation methodology is appropriate for estimating the fair value of warrants. The value allocated to the relative fair value of the Warrants was recorded as debt issuance costs and additional paid in capital. The principal, net of the original issue discount and debt issuance costs, including the allocated relative fair value of the Warrants, which are being recognized over the life of the $440,000 Note, along with associated interest, is recorded with current liabilities on the Company’s condensed consolidated balance sheets. As of September 30, 2022, the $440,000 Note had $ 4,219 89,860 32,329

Preferred Stock

Preferred Stock	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Preferred Stock	Note 8. Preferred Stock Series A Preferred Stock The shares of Series A Preferred Stock have a stated value of $ 0.25 0.05 Series A-2 Preferred Stock On December 30, 2021, the Company issued 2,644,424 286,078 The rights of holders of the Company’s common stock with respect to the payment of dividends and upon liquidation are junior in right of payment to holders of the Series A-2 Convertible Preferred Shares. The rights of the holders of the Company’s Series A-2 Preferred Shares are pari passu to the rights of the holders of the Company’s Series A Preferred Shares currently outstanding. Holders of the Series A-2 Convertible Preferred Stock will vote on an as converted basis with the holders of the Company’s common stock and Series A Preferred Shares as to all matters to be voted on by the holders of the common stock. Each Series A-2 Preferred Share shall be entitled to a number of votes equal to five times the number of shares of common stock into which it is then convertible on the applicable record date.

Loss Per Common Share

Loss Per Common Share	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Loss Per Common Share	Note 9. Loss Per Common Share The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share Schedule of Anti-dilutive Securities Excluded From Calculation of Earning Per Share Three Months Ended September 30, Nine Months Ended 2022 2021 2022 2021 Stock options 1,100,000 1,100,000 1,100,000 1,100,000 Stock warrants 1,576,647 1,019,793 1,576,647 1,019,793 Total shares excluded from calculation 2,676,647 2,119,793 2,676,647 2,119,793

Stock-based Compensation

Stock-based Compensation	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation	Note 10. Stock-based Compensation During the three months ended September 30, 2022 and 2021, there was $6,000 and $8,921, respectively, in stock-based compensation associated with stock options included in Research and development expense. During the nine months ended September 30, 2022 and 2021, there was $ 23,842 26,762 Schedule of Stock-based Compensation Expenses Three Months Ended Nine Months Ended 2022 2021 2022 2021 Research and development $ - $ - $ - $ 29,031 Sales and marketing - 49,703 - 98,332 General and administrative - 19,788 6,968 67,965 Total expense – shares issued for services $ - $ 69,491 $ 6,968 $ 195,328 During the nine months ended September 30, 2021 there were 450,000 0.65 three years five years During the nine months ended September 30, 2022 there were no options granted. As of September 30, 2022, there was $ 12,000 1,100,000 6 0.12 The fair value of all options granted is determined using the Black-Scholes option-pricing model. The following weighted-average assumptions were used: Schedule of Fair Value of Option Grant of Weighted-average Assumptions Nine Months Ended Nine Months Ended Risk-free interest rate N/A 0.21 % Expected life of the options N/A 3.5 Expected volatility of the underlying stock N/A 76.3 % Expected dividend rate N/A 0 % The risk-free interest rates are derived from the U.S. Treasury yield curve in effect on the date of grant for instruments with a remaining term similar to the expected term of the options. The expected life of the options is based on the option term. Due to the Company’s limited historical data, the expected volatility is calculated based upon the historical volatility of comparable companies whose share prices are publicly available for a sufficient period of time. The dividend rate is based on the Company never paying or having the intent to pay any cash dividends. Options outstanding at September 30, 2022 consist of: Schedule of Options Outstanding and Exercisable Date Issued Number Number Exercise Price Expiration Date March 12, 2020 500,000 500,000 $ 0.40 March 12, 2025 June 27, 2020 150,000 150,000 $ 0.40 June 27, 2025 January 1, 2021 450,000 300,000 $ 0.65 December 31, 2025 Total 1,100,000 950,000 Warrants outstanding at September 30, 2022 consist of: Schedule of Warrants Outstanding and Exercisable Date Issued Number Number Exercise Price Expiration Date March 16, 2021 15,900 15,900 $ 0.75 March 15, 2023 May 7, 2021 53,704 53,704 $ 0.74 May 6, 2023 June 17, 2021 12,189 12,189 $ 0.83 June 16, 2023 August 10, 2021 930,000 930,000 $ 1.25 August 9, 2024 February 23, 2022 14,854 14,854 $ 0.705 February 22, 2024 July 19, 2022 550,000 550,000 $ 0.50 July18, 2025 Total 1,576,647 1,576,647

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Note 11. Related Party Transactions Convertible notes payable, related party:

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Note 12. Income Taxes For the nine month period ended September 30, 2022 and the year ended December 31, 2021, the Company did not record a tax provision as the Company did not earn any taxable income in either period and maintains a full valuation allowance against its net deferred tax assets.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 13. Commitments and Contingencies On February 9, 2021, the Company entered into a Receivables Purchase and Security Agreement (“Factoring Agreement”) with a Factoring Company. The Factoring Agreement has an initial term of one year Under the terms of the agreement, designated receivables are sold for periodic advances of up to $ 150,000 10 1.8 As of September 30, 2022, the balance of outstanding invoices that the Factoring Company may assign back to the Company if not collected within 90 days is included in the Company’s Accounts Receivable balance with the amounts received, net of reserves held, included with other current liabilities on the condensed consolidated balance sheets. The net amount included in other current liabilities is $ 6,519 25,420 There are no pending or threatened legal proceedings as of September 30, 2022. The Company has no non-cancellable operating leases.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 14. Subsequent Events Management has evaluated subsequent events through the date of this filing.

Basis of Presentation (Policies

Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates
Principles of Consolidation	Principles of Consolidation
Cash and Cash Equivalents	Cash and Cash Equivalents
Accounts Receivable	Accounts Receivable
Inventories	Inventories
Capitalized Software Development Costs	Capitalized Software Development Costs Internal-Use Software The estimated useful lives of software are reviewed at least annually and will be tested for impairment whenever events or changes in circumstances occur that could impact the recoverability of the assets. Capitalized software development costs for internal-use software net of amortization expense totaled $ 186,159 186,271 37,231 0 no
Intangible Assets	Intangible Assets Business Combination, Related Issues, Initial Measurement Intangibles, General Intangibles Other Than Goodwill Schedule of Indefinite-Lived Intangible Assets U.S. Method Patent 13.4 Web Domain Indefinite life Trademark Indefinite life The estimated useful lives and carrying value of the assets are reviewed at least annually or whenever events or circumstances may result in an impact to the value of the assets.
Convertible Notes Payable	Convertible Notes Payable Derivatives and Hedging Debt with Conversion and Other Options
Revenue Recognition	Revenue Recognition Pursuant to ASC Topic 606, Revenue from Contracts with Customers, To determine the revenue to be recognized for transactions that the Company determines are within the scope of ASC 606, the Company follows the established five-step framework as follows: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract(s); (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract(s); and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company sells allergy diagnostic-related products and immunotherapy treatments to physicians. Revenue is recognized once the Company satisfies its performance obligation which occurs at the point in time when title and possession of products have transitioned to the customer, typically upon delivery of the products. During 2022, the Company began entering into SaaS subscription agreements to provide physicians with access to the Company’s proprietary internally-developed QHSLab platform software that provides clinical decision support and patient monitoring The Company includes shipping and handling fees billed to customers in revenue. There are several practical expedients and exemptions allowed under ASC 606 that impact timing of revenue recognition and disclosures. The Company elected to treat similar contracts as a portfolio of contracts, as allowed under ASC 606. The contracts that fall within the portfolio have the same terms and management has the expectation that the result will not be materially different from the consideration of each individual contract.
Research and Development	Research and Development For the three months ended September 30, 2022 and 2021, there were $48,405 and $19,609 of research and development expenses incurred, respectively. For the nine months ended September 30, 2022 and 2021, there were $ 135,998 62,901 of research and development expenses incurred, respectively.
Stock-based Compensation	Stock-based Compensation Share Based Payment
Earnings Per Common Share	Earnings Per Common Share
Income Taxes	Income Taxes Accounting for Income Taxes, The Company has net operating losses of $ 3,298,699 begin to expire in 2027
Recently Issued Accounting Standards	Recently Issued Accounting Standards In August 2020, the Financial Accounts Standards Board (“FASB”) issued Accounting Standards Updates (“ASU”) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) This Quarterly Report on Form 10-Q does not discuss recent pronouncements that are not anticipated to have a current and/or future impact on or are unrelated to the Company’s financial condition, results of operations, cash flows or disclosures.

Basis of Presentation (Tables)

Basis of Presentation (Tables)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Schedule of Indefinite-Lived Intangible Assets	Schedule of Indefinite-Lived Intangible Assets U.S. Method Patent 13.4 Web Domain Indefinite life Trademark Indefinite life

Accounts Receivable (Tables)

Accounts Receivable (Tables)	9 Months Ended
	Sep. 30, 2022
Credit Loss [Abstract]
Schedule of Accounts Receivable	Schedule of Accounts Receivable September 30, December 31, Accounts receivable $ 67,267 $ 70,474 Allowance for doubtful accounts (9,173 ) - Accounts receivable, net $ 58,094 $ 70,474

Capitalized Software and Inta_2

Capitalized Software and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Non-current assets consist of the following at September 30, 2022 and December 31, 2021: Schedule of Intangible Assets Estimated September 30, December 31, Capitalized Software 3.0 $ 223,390 $ 186,271 Accumulated amortization (37,231 ) - Capitalized Software, net $ 186,159 $ 186,271 Intangible Assets: U.S. Method Patent 13.4 $ 967,500 $ 967,500 Web Domain N/A 161,250 161,250 Trademark N/A 483,750 483,750 Total Intangible Assets $ 1,612,500 $ 1,612,500 Accumulated amortization (90,140 ) (36,056 ) Intangible assets, net $ 1,522,360 $ 1,576,444

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	Convertible notes payable at September 30, 2022 and December 31, 2021, consist of the following: Schedule of Convertible Notes Payable September 30, December 31, Note 1 – Accredited investors $ - $ 25,000 Note 2 – Shareholder 100,000 100,000 Note 3 – Mercer Note 706,000 756,000 Note 4 – Mercer Note #2 440,000 - Total 1,246,000 881,000 Debt discount and issuance costs (122,189 ) (238,896 ) Total convertible notes payable 1,123,811 642,104 Less: current portion 1,123,811 542,104 Non-current portion $ - $ 100,000

Loss Per Common Share (Tables)

Loss Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Schedule of Anti-dilutive Securities Excluded From Calculation of Earning Per Share	Schedule of Anti-dilutive Securities Excluded From Calculation of Earning Per Share Three Months Ended September 30, Nine Months Ended 2022 2021 2022 2021 Stock options 1,100,000 1,100,000 1,100,000 1,100,000 Stock warrants 1,576,647 1,019,793 1,576,647 1,019,793 Total shares excluded from calculation 2,676,647 2,119,793 2,676,647 2,119,793

Stock-based Compensation (Table

Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-based Compensation Expenses	Schedule of Stock-based Compensation Expenses Three Months Ended Nine Months Ended 2022 2021 2022 2021 Research and development $ - $ - $ - $ 29,031 Sales and marketing - 49,703 - 98,332 General and administrative - 19,788 6,968 67,965 Total expense – shares issued for services $ - $ 69,491 $ 6,968 $ 195,328
Schedule of Fair Value of Option Grant of Weighted-average Assumptions	The fair value of all options granted is determined using the Black-Scholes option-pricing model. The following weighted-average assumptions were used: Schedule of Fair Value of Option Grant of Weighted-average Assumptions Nine Months Ended Nine Months Ended Risk-free interest rate N/A 0.21 % Expected life of the options N/A 3.5 Expected volatility of the underlying stock N/A 76.3 % Expected dividend rate N/A 0 %
Schedule of Options Outstanding and Exercisable	Options outstanding at September 30, 2022 consist of: Schedule of Options Outstanding and Exercisable Date Issued Number Number Exercise Price Expiration Date March 12, 2020 500,000 500,000 $ 0.40 March 12, 2025 June 27, 2020 150,000 150,000 $ 0.40 June 27, 2025 January 1, 2021 450,000 300,000 $ 0.65 December 31, 2025 Total 1,100,000 950,000
Schedule of Warrants Outstanding and Exercisable	Warrants outstanding at September 30, 2022 consist of: Schedule of Warrants Outstanding and Exercisable Date Issued Number Number Exercise Price Expiration Date March 16, 2021 15,900 15,900 $ 0.75 March 15, 2023 May 7, 2021 53,704 53,704 $ 0.74 May 6, 2023 June 17, 2021 12,189 12,189 $ 0.83 June 16, 2023 August 10, 2021 930,000 930,000 $ 1.25 August 9, 2024 February 23, 2022 14,854 14,854 $ 0.705 February 22, 2024 July 19, 2022 550,000 550,000 $ 0.50 July18, 2025 Total 1,576,647 1,576,647

Schedule of Indefinite-Lived In

Schedule of Indefinite-Lived Intangible Assets (Details)	9 Months Ended
	Sep. 30, 2022
Web Domain [Member]
Finite-Lived Intangible Assets [Line Items]
Impaired intangible asset	Indefinite life
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Impaired intangible asset	Indefinite life
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, amortization method	13 years 4 months 24 days

Basis of Presentation (Details

Basis of Presentation (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Accounting Policies [Abstract]
Capitalized software development costs	$ 186,159		$ 186,159		$ 186,271
Capitalized computer software, amortization			37,231	$ 0	0
Capitalized computer software, impairments			0		$ 0
Research and development expense	48,405	$ 19,609	135,998	$ 62,901
Operating loss carryforwards	$ 3,298,699		$ 3,298,699
Net operating losses carryforwards, expire date			begin to expire in 2027

Schedule of Accounts Receivable

Schedule of Accounts Receivable (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Credit Loss [Abstract]
Accounts receivable	$ 67,267	$ 70,474
Allowance for doubtful accounts	(9,173)
Accounts receivable, net	$ 58,094	$ 70,474

Schedule of Intangible Assets (

Schedule of Intangible Assets (Details) - USD ($)	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Capitalized Software	$ 223,390	$ 186,271
Accumulated amortization	(37,231)
Capitalized Software, net	186,159	186,271
Intangible Assets:
Total Intangible Assets	1,612,500	1,612,500
Accumulated amortization	(90,140)	(36,056)
Intangible assets, net	$ 1,522,360	1,576,444
Computer Software, Intangible Asset [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, amortization method	3 years
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, amortization method	13 years 4 months 24 days
Intangible Assets:
Total Intangible Assets	$ 967,500	967,500
Web Domain [Member]
Intangible Assets:
Total Intangible Assets	161,250	161,250
Trademarks [Member]
Intangible Assets:
Total Intangible Assets	$ 483,750	$ 483,750

Capitalized Software and Inta_3

Capitalized Software and Intangible Assets (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 23, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Capitalized computer software, amortization				$ 37,231	$ 0	$ 0
Capitalized computer software, impairments				0		$ 0
Acquired intangible assets	$ 1,612,500
Amortization expense		$ 18,028	$ 18,028	$ 54,084	$ 18,028

Loans Payable (Details Narrativ

Loans Payable (Details Narrative) - USD ($)	Mar. 02, 2022	Sep. 30, 2022	Dec. 31, 2021	Jun. 23, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt default long term debt amount		$ 467,807	$ 644,158
Proceeds from loan	$ 128,500
Payments for loan	$ 16,305
Loan payable		$ 41,768	$ 16,793
Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt instrument face amount				$ 750,000

Schedule of Convertible Notes P

Schedule of Convertible Notes Payable (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Total	$ 1,246,000	$ 881,000
Debt discount and issuance costs	(122,189)	(238,896)
Total convertible notes payable	1,123,811	642,104
Less: current portion	1,123,811	542,104
Non-current portion		100,000
Convertible Notes Payable One [Member] | Accredited Investor [Member]
Short-Term Debt [Line Items]
Total		25,000
Convertible Notes Payable Two [Member] | Shareholder [Member]
Short-Term Debt [Line Items]
Total	100,000	100,000
Convertible Notes Payable Three [Member] | Mercer Street Global Opportunity Fund LLC [Member]
Short-Term Debt [Line Items]
Total	706,000	756,000
Convertible Notes Payable Four [Member] | Mercer Street Global Opportunity Fund LLC [Member]
Short-Term Debt [Line Items]
Total	$ 440,000

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)

3 Months Ended

Jul. 27, 2022

Jul. 19, 2022

Feb. 23, 2022

Nov. 11, 2021

Aug. 10, 2021

May 07, 2021

Dec. 23, 2020

Sep. 30, 2022

Mar. 31, 2022

Jun. 30, 2021

Mar. 31, 2021

Oct. 17, 2022

Aug. 10, 2022

Dec. 31, 2021

Nov. 15, 2021

Short-Term Debt [Line Items]

Conversion of notes payable

$ 50,000

$ 27,925

$ 132,075

$ 194,211

Securities Purchase Agreement [Member] | 806,000 Note [Member] | Mercer Street Global Opportunity Fund LLC [Member]

Short-Term Debt [Line Items]

Conversion of notes payable, shares

76,923

Debt instrument convertible conversion price per share

$ 0.65

Conversion of notes payable

$ 50,000

Convertible Notes Payable One [Member] | Accredited Investor [Member]

Short-Term Debt [Line Items]

Debt instrument, principal amount

$ 25,000

$ 25,000

Debt Instrument, Maturity Date

Sep. 25, 2020

Interest payable, current

0

$ 2,555

Conversion of notes payable, shares

59,415

Debt instrument convertible conversion price per share

$ 0.47

Number of Securities Called by Warrants or Rights

14,854

Exercise Price of Warrants or Rights

$ 0.705

Convertible Notes Payable Two [Member] | Shareholder [Member]

Short-Term Debt [Line Items]

Debt instrument, principal amount

$ 100,000

Debt Instrument, Maturity Date

Sep. 30, 2022

Interest payable, current

14,000

6,521

Debt instrument interest rate stated percentage

10%

Debt Instrument, Description

The Company may satisfy the Note upon maturity or Default, as defined, by the issuance of common shares at a conversion price equal to the greater of a 25% discount to the 15-day average market price of the Company’s common stock or $0.50. The principal and interest accrued are convertible at any time through the maturity date of September 30, 2022 at the option of the holder using the same conversion calculation

Convertible Notes Payable Three [Member] | Securities Purchase Agreement [Member] | 806,000 Note [Member]

Short-Term Debt [Line Items]

Debt instrument, principal amount

$ 806,000

Debt instrument convertible conversion price per share

$ 0.0065

$ 0.0065

Number of Securities Called by Warrants or Rights

930,000

930,000

Exercise Price of Warrants or Rights

$ 1.25

Debt instrument interest rate stated percentage

5%

5%

Proceeds from Warrant Exercises

$ 750,000

Warrants term

3 years

Convertible Notes Payable Three [Member] | Securities Purchase Agreement [Member] | 806,000 Note [Member] | Mercer Street Global Opportunity Fund LLC [Member]

Short-Term Debt [Line Items]

Debt instrument, principal amount

$ 50,000

706,000

Interest payable, current

43,273

15,446

Conversion of notes payable, shares

250,000

Debt instrument convertible conversion price per share

$ 0.20

$ 0.20

Original issue discount

$ 440,000

Unamortized debt issuance expense

0

204,835

Remaining debt discount

$ 34,060

Convertible Notes Payable Four [Member] | Securities Purchase Agreement [Member] | 440,000 Note [Member] | Mercer Street Global Opportunity Fund LLC [Member]

Short-Term Debt [Line Items]

Debt instrument, principal amount

$ 440,000

Interest payable, current

4,219

Debt instrument convertible conversion price per share

$ 0.20

Exercise Price of Warrants or Rights

$ 0.50

Debt instrument interest rate stated percentage

5%

Proceeds from Warrant Exercises

$ 400,000

Warrants to purchase common stock

550,000

Total unamortized debt issuance costs

89,860

Debt instrument, unamortized discount

$ 32,329

Preferred Stock (Details Narrat

Preferred Stock (Details Narrative) - USD ($)	Dec. 30, 2021	Sep. 30, 2022	Dec. 31, 2021	Sep. 01, 2019
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock stated value		$ 0.0001	$ 0.0001	$ 0.25
Debt instrument convertible conversion price per share				$ 0.05
Series A2 Convertible Preferred Shares [Member]
Class of Stock [Line Items]
Stock issued during period, shares	2,644,424
Debt instrument face amount	$ 286,078

Schedule of Anti-dilutive Secur

Schedule of Anti-dilutive Securities Excluded From Calculation of Earning Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from calculation	2,676,647	2,119,793
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from calculation	1,100,000	1,100,000
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from calculation	1,576,647	1,019,793

Schedule of Stock-based Compens

Schedule of Stock-based Compensation Expenses (Details) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total expense – shares issued for services	$ 6,968	$ 195,328
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total expense – shares issued for services		29,031
Selling and Marketing Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total expense – shares issued for services		98,332
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total expense – shares issued for services	$ 6,968	$ 67,965

Schedule of Fair Value of Optio

Schedule of Fair Value of Option Grant of Weighted-average Assumptions (Details)	9 Months Ended
	Sep. 30, 2021
Share-Based Payment Arrangement [Abstract]
Risk-free interest rate	0.21%
Expected life of the options	3 years 6 months
Expected volatility of the underlying stock	76.30%
Expected dividend rate	0%

Schedule of Options Outstanding

Schedule of Options Outstanding and Exercisable (Details)	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Option One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Date Issued	Mar. 12, 2020
Number Outstanding	500,000
Number Exercisable	500,000
Exercise Price | $ / shares	$ 0.40
Expiration Date	Mar. 12, 2025
Option Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Date Issued	Jun. 27, 2020
Number Outstanding	150,000
Number Exercisable	150,000
Exercise Price | $ / shares	$ 0.40
Expiration Date	Jun. 27, 2025
Option Three [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Date Issued	Jan. 01, 2021
Number Outstanding	450,000
Number Exercisable	300,000
Exercise Price | $ / shares	$ 0.65
Expiration Date	Dec. 31, 2025
Options Held [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number Outstanding	1,100,000
Number Exercisable	950,000

Schedule of Warrants Outstandin

Schedule of Warrants Outstanding and Exercisable (Details)	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Warrant One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Date Issued	Mar. 16, 2021
Number Outstanding	15,900
Number Exercisable	15,900
Exercise Price | $ / shares	$ 0.75
Expiration Date	Mar. 15, 2023
Warrant Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Date Issued	May 07, 2021
Number Outstanding	53,704
Number Exercisable	53,704
Exercise Price | $ / shares	$ 0.74
Expiration Date	May 06, 2023
Warrant Three [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Date Issued	Jun. 17, 2021
Number Outstanding	12,189
Number Exercisable	12,189
Exercise Price | $ / shares	$ 0.83
Expiration Date	Jun. 16, 2023
Warrant Four [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Date Issued	Aug. 10, 2021
Number Outstanding	930,000
Number Exercisable	930,000
Exercise Price | $ / shares	$ 1.25
Expiration Date	Aug. 09, 2024
Warrant Five [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Date Issued	Feb. 23, 2022
Number Outstanding	14,854
Number Exercisable	14,854
Exercise Price | $ / shares	$ 0.705
Expiration Date	Feb. 22, 2024
Warrant Six [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Date Issued	Jul. 19, 2022
Number Outstanding	550,000
Number Exercisable	550,000
Exercise Price | $ / shares	$ 0.50
Expiration Date	Jul. 18, 2025
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number Outstanding	1,576,647
Number Exercisable	1,576,647

Stock-based Compensation (Detai

Stock-based Compensation (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Stock-based compensation	$ 23,842	$ 26,762
Unrecognized compensation related to unvested options	$ 12,000
Unrecognized compensation related to unvested options, shares	1,100,000
Recognized weighted-average period	6 months
Weighted-average fair value for options granted		$ 0.12
Scientific and Business Advisors [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Number of options granted		450,000
Weighted-average exercise price		$ 0.65
Options vesting term		3 years
Options expiration period		5 years

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Feb. 09, 2021	Sep. 30, 2022	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Other current liabilities		$ 85,612	$ 58,615
Factoring Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Agreement term	1 year
Advances on sale on receivables	$ 150,000
Reserve of purchased receivables, percentage	10%
Factoring fees, percentage	1.80%
Other current liabilities		$ 6,519	$ 25,420